Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 390-395     DOI: 10.1007/s11684-009-0087-5
Research articles |
Construction and humoral immune response of Epstein-Barr virus latent membrane protein 2 DNA vaccine in mice
Jianqing PAN PhD1,Qin ZHANG MD2,Daowen WANG MD, PhD2,
1.Department of Internal Medicine, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan 430030, China;Research Center for Neural Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen 518055, China; 2.Department of Internal Medicine, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan 430030, China;
Download: PDF(475 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  We constructed a eukaryotic expression plasmid encoding Epstein-Barr virus latent membrane protein 2 (EBV, LMP2) and evaluated its effects on humoral immunity. First, the encoding sequence of the EBV LMP2 was amplified from B95−8 cell RNA by reverse transcription polymerase chain reaction (RT-PCR) and then was directionally cloned into eukaryotic expression vector pcDNA3.1. It was employed to evaluate immune response of the mice inoculated doubly with the DNA vaccine. The serum antibody against LMP2 was detected with enzyme-linked immunosorbent assay (ELISA). The recombinant plasmid pcDNA3.1-LMP2 was confirmed by the restrictive endonuclease analysis and sequence analysis. The serum titer of IgG antibody against LMP2 epitope in the mice immunized with the DNA vaccine encoding LMP2 was up to 1∶4000. In conclusion, the EBV LMP2 DNA vaccine can induce a strong humoral immune response in mice.
Keywords Epstein-Barr virus      latent membrane protein 2      nasopharyngeal carcinoma      humoral immunity      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0087-5     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/390
Dolan A, Addison C, Gatherer D, Davison A J, McGeoch D J. The genome of Epstein-Barrvirus type 2 strain AG876. Virology, 2006, 350(1): 164–170

doi: 10.1016/j.virol.2006.01.015
Mourad W, Alsohaibani M O, Saddik M, Bazerbashi S. Epstein-Barrvirus expression in Hodgkin’s disease: Correlation with histologicsubtypes and T and B lymphocyte distribution. Ann Saudi Med, 1998, 18(4): 296–300
Yilmaz A, Hazar V, Akcam M, Inanc-Gurer E, Ceken K, Artan R. Burkitt’s lymphoma following a pediatric livertransplantation: predictive negative value of serologic response toEpstein-Barr virus. Turk J Pediatr, 2007, 49(4): 434–436
Jung I M, Chung J K, Kim Y A, Kim J E, Heo S C, Ahn Y J, Hwang K T, Kim B G, Lee K L, Kim C W, Kim W H, Chang M S. Epstein-Barr virus, beta-catenin,and E-cadherin in gastric carcinomas. JKorean Med Sci, 2007, 22(5): 855–861

doi: 10.3346/jkms.2007.22.5.855
Villa M L, Bombardieri E. LYDMA-antigens and immunityagainst EBV-infected cells Epstein-Barr virus as a model for the studyof host-infection interaction. Int J BiolMarkers, 1987, 2(2): 125–132
Ten Napel C H, The T H, Van Egten-Bijker J, de Gast G C, Halie M R, Langenhuysen M M. Discordance of Epstein-Barr Virus (EBV)specific humoral and cellular immunity in patients with malignantlymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity. Clin Exp Immunol, 1978, 34(3): 338–346
Feltkamp M C, Smits H L, Vierboom M P, Minnaar R P, de Jongh B M, Drijfhout J W, ter Schegget J, Melief C J, Kast W M. Vaccination with cytotoxic T lymphocyte epitope-containingpeptide protects against a tumor induced by human papillomavirus type16-transformed cells. Eur J Immunol, 1993, 23(9): 2242–2249

doi: 10.1002/eji.1830230929
Cheung A K, Lung H L, Hung S C, Law E W, Cheng Y, Yau W L, Bangarusamy D K, Miller L D, Liu E T, Shao J Y, Kou C W, Chua D, Zabarovsky E R, Tsao S W, Stanbridge E J, Lung M L. Functional analysis of a cell cycle-associated, tumor-suppressivegene, protein tyrosine phosphatase receptor type G, in nasopharyngealcarcinoma. Cancer Res, 2008, 68(19): 8137–8145

doi: 10.1158/0008-5472.CAN-08-0904
Armstrong R W, Imrey P B, Lye M S, Armstrong M J, Yu M C, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: saltedfish and other dietary exposures. Int JCancer, 1998, 77(2): 228–235

doi: 10.1002/(SICI)1097-0215(19980717)77:2<228::AID-IJC11>3.0.CO;2-7
Sanguineti G, Bossi P, Pou A, Licitra L. Timingof chemoradiotherapy and patient selection for locally advanced nasopharyngealcarcinoma. Clin Oncol (R Coll Radiol), 2003, 15(8): 451–460

doi: 10.1016/S0936-6555(03)00201-2
Cheng S H, Yen K L, Jian J J, Tsai S Y, Chu N M, Leu S Y, Chan K Y, Tan T D, Cheng J C, Hsieh C Y, Huang A T. Examining prognostic factors and patterns of failure in nasopharyngealcarcinoma following concomitant radiotherapy and chemotherapy: impacton future clinical trials. Int J RadiatOncol Biol Phys, 2001, 50(3): 717–726

doi: 10.1016/S0360-3016(01)01509-7
Nguyen-Van D, Ernberg I, Phan-Thi Phi P, Tran-Thi C, Hu L. Epstein-Barr virus geneticvariation in Vietnamese patients with nasopharyngeal carcinoma: full-lengthanalysis of LMP1. Virus Genes, 2008, 37(2): 273–281

doi: 10.1007/s11262-008-0262-9
Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R. Therapeutic LMP1 polyepitopevaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood, 2003, 101(8): 3150–3156

doi: 10.1182/blood-2002-10-3092
Duraiswamy J, Bharadwaj M, Tellam J, Connolly G, Cooper L, Moss D, Thomson S, Yotnda P, Khanna R. Induction of therapeutic T-cell responses to subdominanttumor-associated viral oncogene after immunization with replication-incompetentpolyepitope adenovirus vaccine. CancerRes, 2004, 64(4): 1483–1489

doi: 10.1158/0008-5472.CAN-03-2196
[1] Lijuan Hu,Zhirui Lin,Yanheng Wu,Juqin Dong,Bo Zhao,Yanbing Cheng,Peiyu Huang,Lihua Xu,Tianliang Xia,Dan Xiong,Hongbo Wang,Manzhi Li,Ling Guo,Elliott Kieff,Yixin Zeng,Qian Zhong,Musheng Zeng. Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing[J]. Front. Med., 2016, 10(1): 61-75.
[2] Hong-Lian RUAN, Feng-Hua XU, Wen-Sheng LIU, Qi-Sheng FENG, Li-Zhen CHEN, Yi-Xin ZENG, Wei-Hua JIA, . Alcohol and tea consumption in relation to the risk of nasopharyngeal carcinoma in Guangdong, China[J]. Front. Med., 2010, 4(4): 448-456.
[3] Jing CHEN MD, Guang-Yuan HU MD, Guo-Qing HU MD, Hua WU PhD, . Technetium-99m-sestamibi SPECT for the diagnosis and follow-up of nasopharyngeal carcinoma[J]. Front. Med., 2010, 4(1): 96-100.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed